Arena Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option SAN DIEGO, Aug. 10 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the underwriters led by ING Barings LLC, Prudential Securities Incorporated, and SG Cowen Securities Corporation, have exercised
Arena Pharmaceuticals, Inc. Announces Initial Public Offering Of 6,000,000 Shares of Common Stock SAN DIEGO, July 28 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that its initial public offering of 6,000,000 shares of its common stock was priced at $18 per share, above
Arena Pharmaceuticals, Inc. Listed on Nasdaq National Market System Following Initial Public Offering July 28, 2000--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA - news ) was admitted to the Nasdaq National Market System following its initial public offering of 6 million shares at $18 per share.
Arena prices 6 mln IPO at $18/shr, above range NEW YORK, July 27 (Reuters) - Arena Pharmaceuticals Inc. (Nasdaq: ARNA - news ) sold 6 million shares at $18 per share, above the estimated price range, in its initial public offering on Thursday, according to the lead underwriters.
Arena Pharmaceutcals raises IPO to 6 mln shares WASHINGTON, July 25 (Reuters) - Arena Pharmaceuticals Inc. on Tuesday raised its initial public offering (IPO) to 6 million shares of common stock from 5 million shares. The company, which says it has developed technology that identifies drug
Arena Pharmaceutucals to offer 5 million shares in IPO WASHINGTON, June 22 (Reuters) - Arena Pharmaceuticals Inc., which says it has found a new way of finding new drug candidates more efficiently, on Thursday said it will offer five million shares in a projected price range of $15-$17 per share
Lilly and Arena Form Drug Discovery Alliance INDIANAPOLIS, April 17 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Arena Pharmaceuticals, Inc., announced today that they have entered into an agreement to develop a number of orphan G-protein coupled receptors (GPCRs) as drug screening
Arena Pharmaceuticals Begins Receptor Drug Discovery Collaboration With Fujisawa SAN DIEGO, Jan. 31 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ("Arena"), a privately held biopharmaceutical company, today announced that Arena and Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan ("Fujisawa") have